NCT06014541View on ClinicalTrials.gov

Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Active, not recruitingOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

October 3, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Trial Locations (5)

19104

Children's Hospital of Philadelphia, Philadelphia

37203

Vanderbilt University Medical Center, Nashville

55101

Gillette Children's Specialty Healthcare, Saint Paul

77030

Baylor College of Medicine, Houston

92123

UCSD - Rady Children's Hospital, San Diego

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY